Conformis logo
Conformis CFMS
report update icon

Quarterly report 2023-Q2
added 05-16-2026

Conformis Balance Sheet 2022-2011 | CFMS

Brief overview of Conformis's financial position

This overview follows the five latest available annual observations between 2018 and 2022.

Assets reached $94 million, compared with $63 million at the beginning. Growth of +49.3% and CAGR near 10.5% show active expansion.

Liabilities followed the scale of the balance sheet: +48.9% versus +49.3% for assets. Leverage did not change materially.

The equity ratio reached 57.6% from 57.5%. A high capital share reduces dependence on liabilities.

The balance sheet holds more cash than interest-bearing debt; net debt is -$26.2 million, indicating minimal leverage.

The cash share moved from 26% to 51.7%. A higher figure generally provides more room in an adverse scenario.

The accumulated result is -$581.3 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.

Conclusion

Conformis's financial position is positive on balance sheet evidence. Growth in resources has not undermined capital strength.

Annual Balance Sheet Conformis

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-26.2 M -78.4 M -2.05 M -5.3 M -1.59 M 11.3 M -37.3 M -117 M -27.3 M -53.3 M - -

Long Term Debt

20.6 M 20.4 M 25 M 19.6 M 14.8 M 29.7 M - 183 K 10.3 M 953 K - -

Long Term Debt Current

1.93 M 1.83 M 1.62 M 1.47 M - - - 295 K 272 K - - -

Total Non Current Liabilities

- - 29.2 M 38.2 M 15.4 M 34.4 M 4.48 M 5.03 M 10.6 M 1.49 M - -

Total Current Liabilities

14.1 M 18 M 30.9 M 17.9 M 11.4 M 12.9 M 14.3 M 13.1 M 10.8 M - - -

Total Liabilities

39.9 M 44.8 M 60.1 M 56 M 26.8 M 47.3 M 18.8 M 18.2 M 21.5 M 14.9 M - -

Deferred Revenue

215 K - 14 M - - 305 K 305 K 305 K - - - -

Retained Earnings

-581 M -531 M -528 M -504 M -476 M -437 M -383 M -325 M -268 M -222 M - -

Total Assets

94 M 145 M 71.5 M 72.4 M 63 M 93.8 M 113 M 159 M 71.3 M 83.9 M - -

Cash and Cash Equivalents

48.7 M 101 M 28.7 M 26.4 M 16.4 M 18.3 M 37.3 M 117 M 37.9 M 54.2 M - -

Book Value

54.2 M 101 M 11.4 M 16.3 M 36.2 M 46.5 M 94.1 M 141 M 49.8 M 69 M - -

Total Shareholders Equity

54.2 M 101 M 11.4 M 16.3 M 36.2 M 46.5 M 94.1 M 141 M 49.8 M 69 M - -

All numbers in USD currency

Quarterly Balance Sheet Conformis

2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

20.6 M 20.6 M 20.6 M 20.5 M 20.4 M 20.4 M 20.4 M 20.8 M 20.6 M 25.2 M 25 M 24.8 M 24.7 M 19.8 M 19.6 M 19.4 M 19.3 M 13.6 M 14.8 M 29.7 M 29.7 M 29.7 M 29.7 M 29.6 M 29.6 M 14.7 M - - 27 K 105 K 183 K 258 K 10.2 M 183 K 10.3 M 10.3 M 10.3 M - - - - - - - - - - - - -

Total Liabilities

35.8 M 37.3 M 39.9 M 43.4 M 43.9 M 42.8 M 44.8 M 42.8 M 43 M 58.7 M 60.1 M 61.2 M 59.2 M 54 M 56 M 53.4 M 37.7 M 33.8 M 26.8 M 42.9 M 45.1 M 43.8 M 47.3 M 47.4 M 47.8 M 34.1 M 18.8 M 15.8 M 14.3 M 18.7 M 18.2 M 18.6 M 30.3 M 18.2 M 21.5 M 21.5 M 21.5 M - - - - - - - - - - - - -

Deferred Revenue

585 K 716 K 215 K - - - - - - 14 M 14 M 14 M 12 M 2.02 M - 2.5 M - 2.33 M - - - - 305 K 305 K 305 K 305 K 305 K 305 K 305 K 305 K 305 K 305 K 305 K 305 K - - - - - - - - - - - - - - - -

Retained Earnings

-604 M -591 M -581 M -578 M -562 M -547 M -531 M -515 M -502 M -540 M -528 M -522 M -516 M -513 M -504 M -499 M -490 M -483 M -476 M -466 M -458 M -444 M -437 M -425 M -412 M -400 M -383 M -367 M -354 M -340 M -325 M -310 M -293 M -325 M -268 M -268 M -268 M - - - - - - - - - - - - -

Total Assets

67.8 M 81.9 M 94 M 105 M 117 M 129 M 145 M 158 M 169 M 146 M 71.5 M 80 M 67.6 M 63.5 M 72.4 M 73.3 M 65 M 64.2 M 63 M 86.3 M 94.2 M 104 M 93.8 M 104 M 116 M 114 M 113 M 121 M 130 M 147 M 159 M 174 M 57.9 M 159 M 71.3 M 71.3 M 71.3 M - - - - - - - - - - - - -

Cash and Cash Equivalents

26.2 M 37.8 M 48.7 M 59.6 M 72.6 M 82.7 M 101 M 97.1 M 108 M 105 M 29.1 M 32.9 M 18.2 M 21.5 M 26.4 M 29.4 M 20.7 M 18.6 M 16.4 M 21.7 M 29.1 M 38.1 M 18.3 M 26.5 M 39.2 M 36.4 M 37.3 M 35 M 37.8 M 76.6 M 117 M 139 M 14.5 M 117 M 37.9 M 37.9 M 37.9 M - 54.2 M - - - 39.7 M - - - - - - -

Book Value

32 M 44.6 M 54.2 M 61.2 M 73.4 M 86 M 101 M 115 M 126 M 87.3 M 11.4 M 18.8 M 8.44 M 9.52 M 16.3 M 19.9 M 27.3 M 30.4 M 36.2 M 43.5 M 49.2 M 60.3 M 46.5 M 56.9 M 68.3 M 79.8 M 94.1 M 105 M 116 M 128 M 141 M 155 M 27.5 M 141 M 49.8 M 49.8 M 49.8 M - - - - - - - - - - - - -

Total Shareholders Equity

32 M 44.6 M 54.2 M 61.2 M 73.4 M 86 M 101 M 115 M 126 M 87.3 M 11.4 M 18.8 M 8.44 M 9.52 M 16.3 M 19.9 M 27.3 M 30.4 M 36.2 M 43.5 M 49.2 M 60.3 M 46.5 M 56.9 M 68.3 M 79.8 M 94.1 M 105 M 116 M 128 M 141 M 155 M 27.5 M 141 M 49.8 M 49.8 M 49.8 M - 69 M - - - 43.1 M - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Conformis, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Medical devices

Issuer Price % 24h Market Cap Country
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 57.08 3.84 % $ 8.66 B usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 15.55 0.18 % $ 440 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 8.8 6.24 % $ 642 M israelIsrael
Electromed Electromed
ELMD
$ 29.6 0.27 % $ 245 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.71 0.69 % $ 12 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 80.32 0.36 % $ 4.38 B britainBritain
LENSAR LENSAR
LNSR
$ 8.3 0.24 % $ 99.3 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.34 0.15 % $ 21.2 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Butterfly Network Butterfly Network
BFLY
$ 8.43 0.93 % $ 2.08 B usaUSA
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 125.33 0.02 % $ 4.35 B usaUSA